Ovarian Cyst Management

Classification

Functional Cysts

Other Benign Masses

• Endometrioma ("chocolate cyst"): associated with peritoneal endometriosis; classic sonographic finding is unilocular cyst with low-level "ground-glass" echogenicity
• Dermoid (benign cystic teratoma): most common neoplasm to undergo torsion
• Cystadenomas (serous/mucinous): can replace the entire ovary
• Polycystic ovaries: not truly "cysts"; part of PCOS diagnostic spectrum

Initial Evaluation

History & Examination

• Menstrual and reproductive history, contraceptive use, family history of ovarian/breast cancer
• Abdominal and pelvic exam — note: smooth, mobile mass = more likely benign; fixed, nodular = raises malignancy concern

Laboratory

• β-hCG (all reproductive-age women — must exclude ectopic/pregnancy)
• CBC (if rupture/hemorrhage suspected)
• CA-125: not reliable in premenopausal women (elevated with endometriosis, fibroids, PID, pregnancy); CA-125 >200 in premenopausal women warrants gynecologic-oncology co-management
• Additional tumor markers by clinical context: AFP, LDH (germ cell); inhibin A/B (stromal); CEA, CA19-9 (epithelial in older patients)

Imaging — Cornerstone: Transvaginal Ultrasound (TVUS)

Transvaginal ultrasound of a unilocular ovarian cyst — Berek & Novak's Gynecology

• Size and consistency (unilocular, mixed echogenicity, multiloculated, solid)
• Features raising suspicion for malignancy: size >10 cm, solid components, papillary excrescences, irregularity, ascites
• Specific patterns: endometrioma (ground-glass), dermoid (echogenic with posterior shadowing), corpus luteum (ring of fire on Doppler)

Management by Clinical Scenario

1. Premenopausal — Functional Cyst (Uncomplicated)

• Expectant management is first-line; follicular cysts resolve in 4–8 weeks
• Oral contraceptives (OCPs): do not hasten resolution of existing cysts, but monophasic OCPs reduce risk of developing new functional cysts by suppressing folliculogenesis and ovulation
• Repeat ultrasound in 6–8 weeks to confirm resolution
• Surgery indicated if: persistent beyond 2–3 cycles, enlarging, symptomatic, or features concerning for neoplasm

2. Premenopausal — Suspected Benign Neoplasm

• Adnexal masses ≥8 cm in premenopausal women generally require surgical exploration
• Laparoscopic ovarian cystectomy: preferred approach for dermoid cysts, fibromas, and most benign neoplasms
• Oophorectomy: often required for larger dermoids and cystadenomas that replace the entire ovary
• Laparotomy: reserved for very large masses, equivocal diagnosis, or suspected malignancy
• Gynecologic oncology consultation when cancer is suspected or complex surgery is anticipated
• — Sabiston Textbook of Surgery

3. Endometrioma

• Many patients managed medically depending on symptoms and fertility desires
• Endometriomas >4 cm are generally refractory to medical management → laparoscopic excision is treatment of choice
• Excision is preferred over drainage (reduces recurrence; preserves fertility better)
• Recent data: women with asymptomatic endometriomas do not need removal prior to ART if the diagnosis is not in question
• — Berek & Novak's Gynecology

4. Postmenopausal

• Any new ovarian cyst in a postmenopausal woman warrants careful evaluation
• Predominantly cystic lesions ≤8 cm may be observed or managed with OCPs for 2 cycles
• Surgical evaluation is appropriate for larger lesions, solid components, or associated symptoms/elevated markers
• — Berek & Novak's Gynecology

5. Pediatric/Premenarcheal

• Adnexal masses ≥2 cm in premenarcheal girls usually require surgical exploration
• Tumor markers: hCG, AFP, LDH; consider CT chest (germ cell tumors can metastasize to lungs/mediastinum)
• Karyotype preoperatively for all premenarcheal girls, especially with dysgerminoma (may arise in dysgenetic gonads)

Complications & Emergency Management

Ruptured Ovarian Cyst

• Corpus luteum cyst is the most common cyst to rupture and cause hemoperitoneum
• Symptoms mimic ectopic pregnancy — always exclude with β-hCG
• Diagnosis: TVUS (quantify free fluid), CBC (falling hematocrit), orthostatic vitals
• Hemodynamically stable, small free fluid → observation ± hospitalization, repeat imaging
• Orthostasis, significant anemia, or large hemoperitoneum → surgical management (laparoscopy preferred, laparotomy if needed)
• Rupture of endometrioma/dermoid → chemical peritonitis; surgical exploration required even without major blood loss

Adnexal Torsion

• Most common neoplasm to torque: dermoid cyst; 83% of torsion occurs in ovaries ≥5 cm
• Presents with acute-onset unilateral pelvic pain + nausea; Doppler flow does NOT rule out torsion
• Urgent surgical management (laparoscopy) — diagnosis often confirmed intraoperatively
• The Ovarian Torsion Composite Index (OT-CI) ≥3 has 100% sensitivity for torsion

Red Flags for Malignancy

Summary Algorithm

Ovarian cyst identified on imaging
        ↓
Is patient pregnant? → Exclude ectopic
        ↓
Premenopausal          Postmenopausal
     ↓                       ↓
Functional cyst?         Any new cyst → evaluate
  → Observe 6–8 wks      ≤8 cm unilocular → observe
  → Resolves → discharge  >8 cm or complex → surgery
  → Persists/enlarges ↓
     Features of neoplasm?
       ↓ Yes
     Laparoscopic cystectomy
     (oncology consult if suspicious)

• Berek & Novak's Gynecology, Chapters 10 & 39 (pp. 452–460, 2378)
• Sabiston Textbook of Surgery, Chapter 29 (pp. 2803–2804)

Treatment of Peripheral Neuropathy

Guiding Principle: Treat the Underlying Cause First

Disease-Specific (Etiologic) Treatment

Symptomatic Pharmacologic Treatment of Neuropathic Pain

First-Line Agents

1. Anticonvulsants (Gabapentinoids) — Best for lancinating/stabbing pain

2. Antidepressants — Effective for both constant and lancinating pain

• Amitriptyline, desipramine, nortriptyline: Start at 10–25 mg at bedtime; increase by similar increments no more than once per week; therapeutic doses typically 75–150 mg
• Mechanism: Block reuptake of norepinephrine and serotonin; inhibit sodium channels
• Desipramine and nortriptyline have fewer anticholinergic and sedating effects → preferred in elderly
• Caution: Avoid in ischemic heart disease, narrow-angle glaucoma, prostatism; anticholinergic effects (constipation, dry mouth, urinary retention), orthostatic hypotension

• Duloxetine 60–120 mg/day: Dual 5-HT and norepinephrine reuptake inhibitor; FDA-approved for DPN; moderate effect
• Venlafaxine 150–225 mg/day: Fewer side effects than TCAs but likely less efficacious
• SSRIs are less effective than TCAs for neuropathic pain

Second-Line Agents

Topical Agents (advantage: minimal systemic side effects)

Tramadol

• 200–400 mg/day; centrally acting; μ-opioid + norepinephrine/serotonin reuptake inhibition
• Effective in painful diabetic and other neuropathies; nausea/constipation in ~20%

Third-Line Agents

Other Anticonvulsants

Opioid Analgesics

• Reserved for failure of adequate trials of first- and second-line agents
• RCTs support oxycodone and levorphanol for PHN and DPN
• Opioids are not first-line for any non-cancer chronic pain — limited evidence for improved quality of life; significant risk of tolerance, hyperalgesia, dependence, addiction
• If used: prefer longer-acting formulations; screen with Opioid Risk Tool; monitor for abuse
• Botulinum toxin A: third-line option; evidence in focal neuropathic pain

Other Adjuvants

• Mexiletine (oral lidocaine): inconsistent results; 100 mg bid, increase slowly
• Ketamine (NMDA antagonist): refractory cases
• Clonidine, baclofen: useful in select patients
• Dextromethorphan: NMDA antagonist; partial relief in DPN but significant sedation/ataxia
• Glucocorticoids (dexamethasone): reduces inflammatory pain; also useful for bone pain

Combination Therapy

• Gabapentin + nortriptyline is more effective than either drug alone in DPN and PHN
• Gabapentin + tramadol or an opioid is a rational combination
• Gabapentinoids and antidepressants act additively

Non-Pharmacologic Treatment

Treatment Hierarchy Summary

PERIPHERAL NEUROPATHY — PAIN MANAGEMENT

Step 1: Treat underlying cause
         ↓
Step 2: First-line pharmacotherapy
         Gabapentin OR Pregabalin
         +/- TCA (amitriptyline/nortriptyline) or SNRI (duloxetine)
         ↓ Inadequate response
Step 3: Second-line
         Add/switch to: Tramadol | Topical lidocaine | Topical capsaicin
         ↓ Still inadequate
Step 4: Third-line
         Opioids (oxycodone) | Botulinum toxin A
         Alternative anticonvulsants (carbamazepine for trigeminal neuralgia)
         ↓ Refractory
Step 5: Multidisciplinary pain clinic
         Spinal cord stimulation | Ketamine | Combination regimens

Drug Dosing Reference

• Bradley and Daroff's Neurology in Clinical Practice, Chapter 106 (pp. 2711–2718)
• Barash, Cullen, and Stoelting's Clinical Anesthesia 9e, Chapter 56 (p. 4776)
• Goldman-Cecil Medicine, Chapter 26 (pp. 271–272)
• Harrison's Principles of Internal Medicine 22E (2025), Chapter 2 (p. 125)
• Textbook of Family Medicine 9e, Chapter 14 (p. 1241)